Home › Focal Segmental Glomerulosclerosis › North Carolina
Focal Segmental Glomerulosclerosis clinical trials in North Carolina
9 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in North Carolina.
Cities in North Carolina
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- UNC Kidney Center- Site Number : 8400021, Chapel Hill
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- Duke University Medical Center, Durham
- Carolina Kidney Associates, Greensboro
- Cardinal Clinical Research, LLC - Shelby, Shelby
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 17, 2026 · NCT07220083Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- University of North Carolina, Chapel Hill
Recruiting
Up to age 21 · All sexes · Updated Aug 28, 2026 · NCT02235857Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
- University of North Carolina, Chapel Hill
Recruiting
Up to age 75 · All sexes · Updated Aug 28, 2026 · NCT04065438A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- Investigator Site #16, New Bern
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT07268638NEPTUNE Match Study
- University of North Carolina Chapel Hill, Chapel Hill
Recruiting
Ages 1 to 80 · All sexes · Updated Jun 10, 2026 · NCT04571658Nephrotic Syndrome Study Network
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke Molecular Physiology Institute, Durham
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
RecruitingPhase 3
Ages 12 to 80 · All sexes · Updated Feb 3, 2026 · NCT05183646From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.